Home › Research › Clinical trials
DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial
E C Wolters, P Riekkinen, A Lowenthal, J J Van der Plaats, J M Zwart, C Sennef. Neurology, 1990-07
Topic: Drug trials: efficacy and safety
We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.
Key findings
- Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP.
- We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Participants115
- Evidence strengthLow
How this study scored 73/100
Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and free to read, so those were left out: it earned 43 of the 59 points we could judge it on, which is 73 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1990 — older than 20 years, still counted |
| Sample size | 2 / 4 | 115 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 2192301) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 43 / 59 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 59 points we could judge it on is 73 out of 100. |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Wolters, E. C., Riekkinen, P., Lowenthal, A., Van der Plaats, J. J., Zwart, J. M., & Sennef, C. (1990). DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial. Neurology. https://doi.org/10.1212/wnl.40.7.1099
Vancouver
Wolters EC, Riekkinen P, Lowenthal A, Van der Plaats JJ, Zwart JM, Sennef C. DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial. Neurology. 1990. doi:10.1212/wnl.40.7.1099. PMID: 2192301.
BibTeX
@article{wolters1990-2192301,
author = {Wolters, E C and Riekkinen, P and Lowenthal, A and Van der Plaats, J J and Zwart, J M and Sennef, C},
title = {{DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial}},
journal = {Neurology},
year = {1990},
doi = {10.1212/wnl.40.7.1099},
pmid = {2192301},
url = {https://doi.org/10.1212/wnl.40.7.1099}
}
Related studies in Clinical trials
Also tagged “cholinesterase”
271 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 271 tagged studies.